In cases where a patient has multiple HER2 results from different assays, the PATHWAY HER2 (4B5) result should be given most weight when considering if patients are eligible for T-DXd in the HER2-low breast cancer setting, until additional data on the clinical utility of other assays for HER2-low scoring becomes available. This evidence concerns the gene ERBB2 and breast cancer.